Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma.

Xu MJ, Wu TJ, van Zante A, El-Sayed IH, Algazi AP, Ryan WR, Ha PK, Yom SS.

J Otolaryngol Head Neck Surg. 2018 Apr 25;47(1):28. doi: 10.1186/s40463-018-0273-z.

2.

Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy.

Xu MJ, Lazar AA, Garsa AA, Arron ST, Ryan WR, El-Sayed IH, George JR, Algazi AP, Heaton CM, Ha PK, Yom SS.

Head Neck. 2018 Jul;40(7):1406-1414. doi: 10.1002/hed.25114. Epub 2018 Mar 10.

PMID:
29524273
3.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

PMID:
29462123
4.

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.

Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A.

Pigment Cell Melanoma Res. 2018 Jan;31(1):110-114. doi: 10.1111/pcmr.12644. Epub 2017 Nov 2.

PMID:
28921907
5.

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI.

JCI Insight. 2017 Jul 20;2(14). pii: 93433. doi: 10.1172/jci.insight.93433. [Epub ahead of print]

6.

Are PD-1 antibodies safe for use in metastatic uveal melanoma?

Tsai KK, Algazi AP.

Melanoma Manag. 2017 May;4(2):79-82. doi: 10.2217/mmt-2017-0007. Epub 2017 May 10. No abstract available.

7.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A.

Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.

8.

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.

Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A.

Br J Cancer. 2017 Apr 25;116(9):1141-1147. doi: 10.1038/bjc.2017.70. Epub 2017 Mar 21.

9.

Head and neck cancer in 2016: A watershed year for improvements in treatment?

Algazi AP, Grandis JR.

Nat Rev Clin Oncol. 2017 Feb;14(2):76-78. doi: 10.1038/nrclinonc.2016.196. Epub 2016 Dec 6. No abstract available.

PMID:
27922045
10.

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.

Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M.

Clin Cancer Res. 2017 Apr 15;23(8):1910-1919. doi: 10.1158/1078-0432.CCR-16-1418. Epub 2016 Oct 10.

11.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.

12.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

13.

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.

Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI.

J Immunother Cancer. 2016 Sep 20;4:58. doi: 10.1186/s40425-016-0162-9. eCollection 2016.

14.

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD.

J Clin Invest. 2016 Sep 1;126(9):3447-52. doi: 10.1172/JCI87324. Epub 2016 Aug 15.

15.

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI.

Br J Cancer. 2015 Apr 14;112(8):1326-31. doi: 10.1038/bjc.2014.541. Epub 2015 Mar 31.

16.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI.

Br J Cancer. 2012 Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29.

17.

New horizons in melanoma treatment: targeting molecular pathways.

Soon CW, Algazi AP, Cha EN, Daud AI.

Ochsner J. 2010 Summer;10(2):93-8. No abstract available.

18.

NRAS-mutant melanoma: response to chemotherapy.

Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI.

Arch Dermatol. 2011 May;147(5):626-7. doi: 10.1001/archdermatol.2011.85. No abstract available.

PMID:
21576590
19.

Treatment of cutaneous melanoma: current approaches and future prospects.

Algazi AP, Soon CW, Daud AI.

Cancer Manag Res. 2010 Aug 17;2:197-211. doi: 10.2147/CMR.S6073.

20.

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.

DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI.

Br J Cancer. 2010 Nov 9;103(10):1548-53. doi: 10.1038/sj.bjc.6605931. Epub 2010 Oct 5.

21.

Biology and treatment of primary central nervous system lymphoma.

Algazi AP, Kadoch C, Rubenstein JL.

Neurotherapeutics. 2009 Jul;6(3):587-97. doi: 10.1016/j.nurt.2009.04.013. Review.

Supplemental Content

Loading ...
Support Center